NasdaqGS:INDV
NasdaqGS:INDVPharmaceuticals

Why Indivior (INDV) Is Up 7.1% After London Delisting for Sole Nasdaq Listing and What's Next

On July 25, 2025, Indivior completed its delisting from the London Stock Exchange, maintaining a sole primary listing on the Nasdaq Stock Market. This shift puts a sharper spotlight on the company's US market focus and may streamline how global investors access Indivior shares. We'll explore how the London delisting sharpens Indivior's profile for US-based investors and influences its investment narrative going forward. This technology could replace computers: discover the 26 stocks are...
NasdaqGS:HON
NasdaqGS:HONIndustrials

Honeywell International (HON) Declares US$1.13 Quarterly Dividend Payment

Honeywell International (HON) recently announced a quarterly dividend affirmation, maintaining investor confidence with a payment of $1.13 per share. Despite market conditions with a broader 1% climb last week and 17% over the last year, Honeywell's 13% price increase over the last quarter stands out. Notably, the company's strong Q2 earnings, raised sales forecast, and strategic alternatives for business restructuring likely strengthened its market position. Executives such as Jim Masso...
NYSE:LLY
NYSE:LLYPharmaceuticals

Eli Lilly (LLY) Gains CHMP Approval for Donanemab in Alzheimer's Treatment

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a crucial therapeutic area. During the same period, LLY registered a 5% share price increase, notably outpacing the broader market's 1% rise over the past week. This uptrend in LLY's stock could be attributed to investors' optimism about donanemab's potential impact. Additionally, the company's...
NYSE:PFE
NYSE:PFEPharmaceuticals

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's...